Metabolomic identification of diagnostic serum-based biomarkers for advanced stage melanoma.
Document Type
Article
Publication Date
8-3-2018
Abstract
INTRODUCTION: Melanoma is a highly aggressive malignancy and is currently one of the fastest growing cancers worldwide. While early stage (I and II) disease is highly curable with excellent prognosis, mortality rates rise dramatically after distant spread. We sought to identify differences in the metabolome of melanoma patients to further elucidate the pathophysiology of melanoma and identify potential biomarkers to aid in earlier detection of recurrence.
METHODS: Using
RESULTS: We accurately quantified 181 metabolites in serum using a combination of
CONCLUSION: Targeted metabolomic analysis demonstrated significant differences in metabolic profiles of advanced stage (III and IV) melanoma patients as compared to controls. These differences may represent a potential avenue for the development of multi-marker serum-based assays for earlier detection of recurrences, allow for newer, more effective targeted therapy when tumor burden is less, and further elucidate the pathophysiologic changes that occur in melanoma.
Volume
14
Issue
8
First Page
105
Last Page
105
Recommended Citation
Bayci AWL, Baker DA, Somerset AE, Turkoglu O, Hothem Z, Callahan RE, Mandal R, Han B, Bjorndahl T, Wishart D, Bahado-Singh R, Graham SF, Keidan R. Metabolomic identification of diagnostic serum-based biomarkers for advanced stage melanoma. Metabolomics. 2018 Aug 3;14(8):105. doi: 10.1007/s11306-018-1398-9. PubMed PMID: 30830422.
ISSN
1573-3890
PubMed ID
30830422